Comparing the current results to its competitors, Editas Medicine Inc reported Revenue decrease in the 1 quarter 2026 year on year by -39.22 %, faster than the overall decrease of Editas Medicine Inc 's competitors by -11.14 %, recorded in the same quarter.
Editas Medicine Inc 's Comment on Competition and Industry Peers
The company operates in a rapidly evolving technological environment with significant competition. Competitors may obtain regulatory approval earlier or develop therapies that are safer, more advanced, or more effective. The company's genomic medicines and gene editing technology involve uncertainties related to pricing, reimbursement, and manufacturing, which may result in production delays. Additionally, challenges to patent protection and licensing terms present risks, as competitors could create similar or identical products if patent scope is limited or contested.
May 14, 2024
Editas Medicine, a leading gene editing company, has recently announced exciting updates in the field of clinical trials. The company is set to present clinical data from the RUBY and EdiTHAL trials of reni-cel at the upcoming European Hematology Association (EHA) Hybrid Congress in Madrid, Spain. The abstracts of these trials have been accepted for both oral and poster presentations, showcasing the significant progress made by Editas Medicine in the field of gene editing.Reni-cel is a groundbreaking gene therapy that aims to address various hematologic disorders. The RUBY trial focuses on the treatment of patients with rare blood disorders, while the EdiTHAL trial focuses on the treatment of patients with b...
May 1, 2024
In a promising stride towards developing innovative therapies for cancer and autoimmune diseases, Editas Medicine and Bristol Myers Squibb (BMS) have announced a two-year extension of their collaboration on the research and development of alpha-beta T cell medicines. This partnership aims to leverage cutting-edge genetic editing technologies to revolutionize the treatment landscape and bring hope to patients facing these debilitating conditions.Collaboration DetailsEditas Medicine, a leading genome editing company, and BMS, a renowned global biopharmaceutical company, are committed to advancing the potential of alpha-beta T cell therapies. These therapies involve harnessing the power of the immune system to ...
Euda Health Holdings Limited operates as a digital health platform that facilitates access to healthcare services. They offer a range of online health consultations and concierge services, enabling users to connect with healthcare professionals and receive personalized medical advice and treatment. Their business model focuses on leveraging technology to streamline the healthcare experience and improve access to quality care for individuals seeking medical assistance.
Maxcyte Inc's business model revolves around providing cell engineering and flow electroporation technology to facilitate drug discovery, development, and manufacturing processes.
Omniab Inc is a technology company that operates on a B2B (business-to-business) model, offering a range of software solutions and services. The company focuses on providing customized software applications to help businesses streamline their operations, enhance productivity, and improve efficiency. Omniab Inc also offers consultation services to assist companies in optimizing their IT infrastructure.
Sources:
Editas Medicine Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Editas Medicine Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
